Schedule an appointment: +91-9829013468

Follow-Up of Patients with Low-Grade Non-Muscle Invasive Bladder Cancer (NMIBC)

Non-muscle invasive bladder cancer (NMIBC) accounts for approximately 75-80% of all bladder cancer cases. Among these, low-grade NMIBC represents a significant subset characterized by a relatively favorable prognosis compared to high-grade tumors. Despite its less aggressive nature, proper follow-up is crucial to prevent recurrence and progression. This article aims to provide a comprehensive overview of the follow-up strategies for patients with low-grade NMIBC, highlighting current medical trends and findings from recent studies.

Low-Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Treatment Best Doctor Jaipur Rajasthan Dr. M Roychowdhury Dr. Rajan Bansal

Understanding Low-Grade NMIBC

Definition and Characteristics

Low-grade NMIBC refers to bladder tumors that have not invaded the muscle layer of the bladder wall and exhibit slow growth with low potential for metastasis. These tumors are generally classified as Ta or T1 lesions:

  • Ta Tumors: Limited to the bladder’s innermost layer (urothelium).
  • T1 Tumors: Invade the connective tissue beneath the urothelium but not the muscle layer.


The prognosis for low-grade NMIBC is generally favorable, with high survival rates. However, recurrence is common, necessitating meticulous follow-up to detect and treat recurrent tumors promptly.

Importance of Follow-Up in Low-Grade NMIBC

Preventing Recurrence and Progression

While low-grade NMIBC rarely progresses to muscle-invasive disease, the risk of recurrence is significant. Follow-up allows for early detection of recurrences, facilitating timely intervention to prevent progression.

Monitoring for New Tumors

Patients with low-grade NMIBC are at risk of developing new tumors in the bladder or elsewhere in the urinary tract. Regular follow-up ensures these new tumors are detected and managed early.

Guiding Treatment Decisions

Follow-up provides essential data to guide treatment decisions, including the need for additional intravesical therapy, repeat resections, or more aggressive treatments if progression is suspected.

Current Medical Trends in Follow-Up Strategies

Frequency and Methods of Surveillance


Cystoscopy remains the cornerstone of NMIBC follow-up, allowing direct visualization of the bladder mucosa to identify recurrences or new tumors. The frequency of cystoscopy typically follows a standardized schedule:

  • Every 3-4 months for the first 2 years.
  • Every 6 months for the next 2-3 years.
  • Annually thereafter.

Urinary Cytology

Urinary cytology involves examining urine samples for the presence of cancer cells. While its sensitivity for detecting low-grade tumors is lower compared to high-grade tumors, it remains a useful adjunct in surveillance protocols.


Imaging studies such as ultrasound every 3 months is mandatory. CT scans or MRI may be used in select cases, particularly when upper urinary tract involvement is suspected.

Emerging Technologies in Surveillance

Blue Light Cystoscopy

Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) has shown promise in improving the detection of bladder tumors, including low-grade lesions. BLC enhances the visualization of tumors by causing them to fluoresce under blue light, which can lead to more accurate detection and resection.

Urinary Biomarkers

Research into urinary biomarkers for bladder cancer surveillance is ongoing, with the goal of identifying non-invasive methods to detect recurrence. Biomarkers such as NMP22, UroVysion, and Bladder EpiCheck are being evaluated for their potential to complement traditional surveillance methods.

Intravesical Therapy in Follow-Up

Mitomycin C (MMC)

Intravesical chemotherapy with MMC is commonly used post-TURBT (transurethral resection of bladder tumor) to reduce recurrence rates. Recent studies suggest that a single postoperative instillation of MMC can significantly decrease the likelihood of recurrence.

Bacillus Calmette-Guérin (BCG)

While BCG is more commonly used for high-grade NMIBC, it may also be employed in selected cases of recurrent low-grade NMIBC. Maintenance BCG therapy can further reduce recurrence rates and is considered in patients with frequent recurrences.

Current Studies and Evidence

Randomized Controlled Trials

Several randomized controlled trials (RCTs) have investigated the optimal follow-up strategies for low-grade NMIBC. For instance, the study by Sylvester et al. (2004) demonstrated that a single postoperative instillation of MMC significantly reduces the risk of recurrence compared to TURBT alone .

Long-Term Cohort Studies

Long-term cohort studies provide valuable insights into the recurrence and progression patterns of low-grade NMIBC. The European Association of Urology (EAU) guidelines, based on extensive cohort data, recommend risk-adapted surveillance schedules to optimize follow-up while minimizing unnecessary procedures .


Meta-analyses synthesizing data from multiple studies have helped establish evidence-based follow-up protocols. For example, a meta-analysis published in BJU International confirmed the efficacy of blue light cystoscopy in reducing recurrence rates compared to white light cystoscopy .

Challenges and Considerations in Follow-Up

Patient Compliance

Ensuring patient compliance with follow-up schedules is a significant challenge. Factors such as the frequency of visits, the invasiveness of procedures, and the potential for anxiety can affect adherence. Educating patients about the importance of regular follow-up and providing psychological support are crucial to improving compliance.


Balancing the need for thorough surveillance with cost-effectiveness is an ongoing concern. While intensive follow-up can lead to earlier detection of recurrences, it also increases healthcare costs. Studies are exploring ways to optimize follow-up schedules to achieve the best outcomes at a reasonable cost.

Quality of Life

The impact of follow-up procedures on patients’ quality of life is an important consideration. Repeated cystoscopies and other surveillance methods can cause discomfort and anxiety. Efforts to develop less invasive and more patient-friendly follow-up strategies are ongoing.

Future Directions in Follow-Up of Low-Grade NMIBC

Personalized Surveillance Protocols

Advancements in molecular diagnostics and risk stratification are paving the way for personalized surveillance protocols. Tailoring follow-up schedules based on individual risk profiles, genetic markers, and tumor characteristics can improve outcomes while reducing the burden on patients.

Integrating Artificial Intelligence

Artificial intelligence (AI) and machine learning are being explored for their potential to enhance bladder cancer surveillance. AI algorithms can analyze imaging and cytology results more accurately and predict recurrence risk, aiding in the development of personalized follow-up plans.

Innovations in Non-Invasive Monitoring

Research into non-invasive monitoring methods, such as advanced urinary biomarkers and liquid biopsies, holds promise for reducing the need for invasive procedures. These innovations could significantly improve patient comfort and compliance while maintaining high surveillance accuracy.


Effective follow-up of patients with low-grade NMIBC is crucial to prevent recurrence and progression. Current medical trends emphasize a combination of cystoscopy, urinary cytology, and selective use of imaging, complemented by emerging technologies like blue light cystoscopy and urinary biomarkers. Intravesical therapies such as MMC and BCG play important roles in reducing recurrence rates. Ongoing research and technological advancements promise to further refine follow-up strategies, making them more personalized, cost-effective, and patient-friendly. Dispelling misconceptions and adhering to evidence-based practices are essential for optimizing the management of low-grade NMIBC and improving patient outcomes.

Best Hospital for Bladder Cancer Treatment in Jaipur – Institute of Urology, C Scheme

The Institute of Urology is renowned as a technically advanced hospital, excelling in the treatment of urinary bladder cancers and a wide range of other urological conditions. Equipped with cutting-edge diagnostic tools and state-of-the-art treatment technologies, the institute offers comprehensive care from early detection to advanced surgical interventions and targeted therapies. Their team of expert urologists employs the latest minimally invasive techniques, such as robotic-assisted surgery and intravesical therapy, ensuring precise treatment with optimal outcomes. The Institute of Urology’s commitment to integrating innovative medical advancements with compassionate, patient-centered care positions it as a leader in urological health, providing top-tier services for all urinary bladder cancers and related urological problems.

We have also started the facility of online consultation so that you can discuss about your problems in detail with our experts from the comfort of your home. Please remember to keep ready all the investigations that you’ve had done so far so that it is helpful for the specialist to guide you precisely about the next course of action. At Institute of Urology, we strictly abide by the International protocols so that we keep up with the latest and best of what the advancements in the medical field has to offer.

Our doctors can be reached Monday to Saturday during working hours.
Dr. M. Roychowdhury – 9929513468/ 9829013468
Dr. Rajan Bansal – 8601539297


  1. Sylvester, R. J., Oosterlinck, W., & van der Meijden, A. P. (2004). A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. Journal of Urology, 171(6 Pt 1), 2186-2190.
  2. European Association of Urology. (2021). EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS). European Association of Urology.
  3. Babjuk, M., Böhle, A., Burger, M., Capoun, O., Cohen, D., Comperat, E. M., … & Zigeuner, R. (2020). EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. European Urology, 76(4), 639-657.
  4. Witjes, J. A., Bruins, H. M., Cathomas, R., Comperat, E. M., Cowan, N. C., Gakis, G., … & van der Heijden, A. G. (2020). European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology, 79(1), 82-104.
  5. Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., … & Dinney, C. P. (2013). Bladder cancer. The Lancet, 388(10061), 2796-2810.
  6. Burger, M., Grossman, H. B., Droller, M. J., Schmidbauer, J., Hermann, G., Drăgoescu, O., … & Filbeck, T. (2013). Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. European Urology, 64(5), 846-854.
Photo of author

Previous Post

Common Urological Problems in Paediatric Patients

Next Post

Follow-Up of Patients with High-Grade Non-Muscle Invasive Bladder Cancer (NMIBC)

Leave a Comment


Call Now